The Best-Vetted Anti-Aging Supplements in 2026 — Based on Human Studies and the ITP

The information in this article is not intended as, and should not be taken as, medical advice. Interventions like exercising, dietary changes, and taking medications and supplements can have both benefits and side effects. Please consult with a medical professional about any medical concerns.

This article begins with a Quick Guide, then goes into more depth. It focuses on compounds with meaningful human clinical trial data or unusually compelling animal research.

Supplements are organized into three tiers based on evidence quality. Tier 1 represents the strongest case for most older adults. Tier 2 compounds are worth serious consideration, with the understanding that the evidence is still developing. Tier 3 explores supplements that might warrant watching as more research becomes available.

The list is not exclusive. Many other compounds are being explored which may turn out to have profound anti-aging benefits. (I’m taking dozens of supplements myself which did not meet the criteria of being vetted in humans.) The ones below are not necessarily the only effective ones, but they are the ones with the strongest evidence, at this point, to support them. The list is limited to supplements; medications such as rapamycin are not included, even if they are very promising.

About Side Effects and Interactions

• Nutritional supplements, like medications, can have side effects.
• A supplement could in theory be good for one person, but bad for another.
• For example, if a person has high blood sugar, a supplement that lowers it might in theory be useful; if they have low blood sugar, the same supplement might in theory be harmful.
• I would always recommend researching both the benefits and possible drawbacks of supplements before taking them, and consulting with a health care professional if you have specific concerns.
• In my own case, I also do a regular blood tests to ascertain whether my supplement protocol is associated with lower or higher, epigenetic age, and adjusting accordingly.
• If you are taking medications, it’s particularly important to check for interactions, and let your healthcare provider know what you are taking — some supplements may affect drug metabolism or efficacy.

Quick Guide: The Best-Vetted Anti-Aging Supplements by Nils Osmar © 2026

TIER 1 — Strongest Human Evidence

GlyNAC (Glycine + N-Acetylcysteine) — The most promising combination supplement, from my perspective, in current aging research. Human Randomized Controlled Trials (RCTs) show improvements across an unusually broad range of aging hallmarks, including mitochondrial function, oxidative stress, inflammation, insulin resistance, muscle strength, and cognitive function.

Creatine Monohydrate — One of the most-studied supplements in existence. Strong evidence for preserving muscle mass and strength in older adults, with emerging data supporting cognitive benefits. Addresses sarcopenia, one of the most consequential drivers of age-related decline. Associated with improvements in memory and cognition in human and animal studies.

Vitamin D3 (with K2) — Functions more like a hormone than a vitamin, with receptors throughout the body. Strong evidence for immune regulation, reduced cancer mortality, and autoimmune protection. K2 is important to take alongside D3 to direct calcium properly.

Magnesium — A cofactor in over 300 enzymatic reactions including DNA repair and mitochondrial energy production. Deficiency is common in older adults. Associated with reduced cardiovascular risk, better insulin sensitivity, and improved sleep.

Omega-3 Fatty Acids (EPA/DHA) — Robust evidence for anti-inflammatory effects and cardiovascular protection. Quality and freshness matter significantly — oxidized fish oil may cause harm rather than benefit.

High-Quality Multivitamin — Recent large-scale trial data (COSMOS-Mind) found multivitamin supplementation equivalent to roughly 1.8 years of reduced cognitive aging over three years. Particularly valuable for correcting the subclinical deficiencies common in older adults.

Glucosamine — The largest and most comprehensive study related to this compound was published in the Annals of the Rheumatic Diseases (Li et al., 2020). It followed 495,077 participants from the UK Biobank over a median of 8.9 years. Among them, 19.1% reported regular glucosamine use at baseline. After adjusting for a wide range of confounders — age, sex, smoking, alcohol, physical activity, BMI, diet, existing diseases, and use of other supplements and medications — the researchers found that regular glucosamine use was associated with:

• 26% lower digestive disease mortality (HR 0.74)
• 15% lower all-cause mortality (HR 0.85)
• 18% lower cardiovascular mortality (HR 0.82)
• 6% lower cancer mortality (HR 0.94)
• 27% lower respiratory disease mortality (HR 0.73)

TIER 2 — Promising Human Data + Strong Mechanistic Basis

NAD+ Precursors (NR, NMN, NA) — Reliably raise NAD+ levels in humans, with NAD+ declining significantly with age. Clinical outcome data is still maturing, but the mechanistic case is strong.

Alpha-Ketoglutarate (AKG) — A key metabolic intermediate that declines with age. Pilot human data using DNA methylation clocks showed promising reductions in biological age. Directly involved in epigenetic regulation.

Astaxanthin — A potent carotenoid antioxidant and the first supplement in ITP history to show lifespan extension in mice. Multiple human RCTs demonstrate reductions in inflammatory markers, improvements in antioxidant capacity, and benefits for skin aging, cardiovascular markers, and immune function.

Beta-Alanine (Carnosine Precursor) — Raises muscle carnosine levels, which decline with age. Anti-glycation properties are mechanistically relevant to multiple age-related conditions.

L-Carnitine / Acetyl-L-Carnitine (ALCAR) — Supports mitochondrial fatty acid metabolism. Human evidence supports cognitive benefits and muscle preservation, particularly in those with low baseline carnitine (vegetarians, vegans, older adults generally).

TIER 3 — Compelling but Earlier Stage — Worth Watching

Fucoidan and Icariin (SIRT6 activators), Taurine, Low-Dose Lithium, and Epicatechin — Each has intriguing mechanisms and suggestive evidence, but human anti-aging trial data is limited. Epicatechin is a newly ITP-validated flavonoid (found naturally in cocoa and dark chocolate) with early human data on vascular function, mitochondrial biogenesis, and muscle preservation. Worth watching closely as research matures.

The Key Principles

• Evidence quality beats marketing claims.
• Tracking biomarkers (inflammation, metabolic panels, grip strength, cognitive function) gives you real feedback.
• The combination problem is real — most supplement research studies compounds in isolation, and we don’t yet know how stacks interact.

More Detailed Information – by Nils Osmar and Claude Opus 4.6

The section below is a collaboration between a human author (Nils) and Claude Opus 4.6. It has been carefully vetted and the references have been double-checked for accuracy. Any errors are the responsibility of the human author.

Scroll through any supplement website and you will encounter hundreds of products claiming to slow aging, extend vitality, or add years to your life. The claims are bold. The evidence behind most of them is thin.

In this article, rather than cataloging everything that has been marketed as anti-aging, we are focusing on supplements supported by actual human studies — or, where human data is still emerging, by unusually compelling evidence from animal models and mechanistic research. I’ve organize the information into tiers, so you can quickly gauge how confident the science actually is.

We also introduce a rigorous benchmark that most supplement articles ignore: the NIA Interventions Testing Program (ITP), a multi-site mammalian longevity study that is arguably the most stringent testing program for anti-aging compounds in the world. When a supplement clears the ITP bar, that is significant. Most do not.

The Hallmarks of Aging: A Scientific Framework

To evaluate anti-aging supplements rigorously, it helps to understand what aging actually is at the biological level. A landmark paper published in Cell (Lopez-Otin et al., 2013, updated 2023) identified twelve core “hallmarks” of aging — biological processes that accumulate damage over time and drive the decline we recognize as getting old.

These hallmarks include:

• Genomic instability — accumulated DNA damage
• Telomere attrition — shortening of protective chromosome caps
• Epigenetic alterations — changes in gene expression patterns
• Loss of proteostasis — decline in protein quality control
• Disabled macroautophagy — impaired cellular self-cleaning
• Deregulated nutrient sensing — dysregulation of pathways like mTOR, AMPK, and sirtuins
• Mitochondrial dysfunction — declining energy production efficiency
• Cellular senescence — accumulation of dysfunctional “zombie” cells
• Stem cell exhaustion — declining regenerative capacity
• Altered intercellular communication — chronic inflammation and disrupted signaling
• Chronic inflammation (“inflammaging”)
• Dysbiosis — disruption of the gut microbiome

When we evaluate supplements, one useful question is: does this compound address one or more of these hallmarks with meaningful evidence? Addressing multiple hallmarks simultaneously — as GlyNAC appears to do — is particularly significant.

Note on lifespan studies in humans: It is currently impossible to conduct true lifespan extension trials in humans. Such trials would require following participants for decades, controlling for countless variables, and defining endpoints that go far beyond what any study can practically manage. This is why we rely heavily on biomarkers associated with the hallmarks of aging, functional outcomes (strength, cognition, inflammation markers), and — where available — results from rigorous mammalian studies.

Reminder: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any new supplement regimen, particularly if you are taking medications or have existing health conditions.

The Combination Problem

Most people who take supplements take more than one. Yet almost all supplement research studies individual compounds in isolation. This creates a significant blind spot.

When multiple supplements are combined, several things could happen:

• Synergistic benefit — compounds reinforce each other’s effects (GlyNAC is itself an example: glycine and NAC together outperform either alone)
• Additive effects — modest benefits stack up without interfering
• Antagonism — one compound reduces or cancels the effect of another
• Altered pharmacokinetics — one compound affects absorption, metabolism, or elimination of another
• Unanticipated side effects from interactions not seen in individual studies

Research on supplement combinations is genuinely scarce. Until better data exists, intellectual honesty requires acknowledging that even a carefully chosen stack of evidence-backed supplements may not behave exactly as individual studies predict. This is not a reason to avoid all supplementation — it is a reason to be thoughtful and to monitor your own responses carefully.

The NIA Interventions Testing Program: The Gold Standard

The Interventions Testing Program (ITP) is funded by the National Institute on Aging and conducted simultaneously at three independent research sites: the University of Michigan, the Jackson Laboratory, and the University of Texas Health Science Center at San Antonio. Testing at three sites simultaneously is critical — it filters out results that are real at one site but fail to replicate elsewhere, a problem that plagues much longevity research.

The ITP uses genetically heterogeneous mice (the UM-HET3 strain) to better model the genetic diversity of real populations, rather than inbred strains that may respond atypically to interventions. Compounds are tested for effects on median and maximum lifespan.

The ITP has tested dozens of compounds. Most fail. The ones that succeed represent a very short list. Among those with confirmed lifespan-extending effects in ITP mice:

• Rapamycin — the most robust and replicated finding, showing lifespan extension even when started in old age. Rapamycin is a prescription mTOR inhibitor, not a freely available supplement.
• Acarbose — an anti-diabetic drug that modulates carbohydrate metabolism. Also not a supplement.
• 17-alpha estradiol — extended lifespan in male mice only.
• Glycine — one of the few freely available supplements to show ITP-confirmed lifespan extension in mice. This is particularly relevant given glycine’s role in GlyNAC supplementation (see Tier 1).
• Astaxanthin — the first supplement (as distinct from a pharmaceutical) to show ITP-confirmed lifespan extension, with median lifespan increase in male mice (2019 cohort). Stage II testing at additional doses is currently in progress.
• Epicatechin — a flavonoid found in cocoa and dark chocolate, confirmed in the 2021 ITP cohort to extend median lifespan by approximately 5% and maximum lifespan by 6% in male mice.
• Canagliflozin — an SGLT2 inhibitor diabetes drug; extended lifespan in males.

The ITP has tested many popular supplements — including resveratrol, curcumin, green tea extract, fish oil, nicotinamide riboside (NR), fisetin, and various antioxidants — and most have not shown convincing lifespan extension under these rigorous conditions. This should give us pause when evaluating marketing claims. (Note: some of these supplements, including fish oil and NR, have strong human evidence for specific health benefits despite their negative ITP lifespan results — the ITP measures mouse lifespan specifically, not all possible benefits.)

Key takeaway: The ITP is the most rigorous mammalian longevity testing program in the world. Compounds that succeed there deserve serious attention. Compounds that fail there — however popular — deserve skepticism. And even ITP success in mice does not guarantee human benefit; it is one important data point, not a verdict.

TIER 1 — Strongest Human Evidence

These supplements have demonstrated meaningful benefits in human clinical trials, with effects relevant to aging, longevity biomarkers, or conditions strongly associated with age-related decline.

GlyNAC (Glycine + N-Acetylcysteine)

GlyNAC is arguably the most exciting combination supplement in current aging research. Both glycine and NAC are precursors to glutathione — the body’s master antioxidant — but human studies suggest they work better together than either does alone, likely because glycine and cysteine (provided by NAC) are the two limiting amino acids in glutathione synthesis.

Key human evidence:

• A 2021 randomized controlled trial by Sekhar et al. (Baylor College of Medicine) found that 16 weeks of GlyNAC supplementation in older adults significantly improved glutathione levels, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genomic damage, and muscle strength.
• A 2022 pilot RCT extended these findings, showing improvements in gait speed, exercise capacity, body composition, and cognitive function — an unusually broad profile of benefits for a single intervention.
• Glycine alone has ITP-confirmed lifespan extension in mice, lending additional mechanistic support.

Hallmarks addressed: mitochondrial dysfunction, genomic instability, oxidative stress (related to proteostasis), chronic inflammation, altered nutrient sensing.

Evidence quality: Multiple human RCTs. Among the strongest evidence profiles in the supplement space.

Typical dosing studied: Glycine 1.33g/kg/day + NAC 0.81g/kg/day (weight-based in research); many people use simpler fixed doses such as 3–6g glycine + 600–1200mg NAC daily.

Creatine Monohydrate

Creatine is primarily associated with athletic performance and muscle building, but its relevance to aging is substantial and increasingly well-documented. It is one of the most studied supplements in existence, with a safety profile spanning decades.

Key evidence in aging contexts:

• Multiple meta-analyses confirm that creatine supplementation combined with resistance training significantly improves muscle mass and strength in older adults, addressing one of the most important risk factors for age-related morbidity and mortality (sarcopenia).
• Emerging evidence suggests cognitive benefits, particularly in older adults and in situations of cognitive stress. A 2022 meta-analysis in Nutrition Reviews found significant improvements in short-term memory and intelligence/reasoning tasks.
• Creatine supports mitochondrial energy production (ATP regeneration) and may have neuroprotective effects.

Hallmarks addressed: stem cell exhaustion (via muscle preservation), mitochondrial dysfunction, altered intercellular communication (inflammation reduction in some studies).

Evidence quality: Extensive human literature. Among the most-studied supplements in existence.

Typical dosing: 3–5g daily of creatine monohydrate. No loading phase required for older adults.

Vitamin D3 (with K2)

Vitamin D deficiency is extraordinarily common in older populations, and the biological roles of vitamin D are far broader than its classic association with bone health. Vitamin D3 functions more like a hormone than a vitamin, with receptors in virtually every tissue of the body.

Key evidence:

• The VITAL trial (2022, NEJM Evidence) found that vitamin D3 supplementation significantly reduced cancer mortality, autoimmune disease incidence, and had positive effects on cardiovascular outcomes in specific subgroups.
• Strong evidence supports improved immune function, reduced all-cause mortality in deficient populations, and protection against respiratory infections.
• Vitamin K2 (specifically MK-7 form) is increasingly co-administered because D3 increases calcium absorption, and K2 directs that calcium to bones rather than arteries — an important combination for older adults.

Hallmarks addressed: altered intercellular communication (immune regulation), chronic inflammation, genomic stability (some evidence of DNA repair support).

Evidence quality: Strong for deficiency correction and specific outcomes. More nuanced for universal supplementation in replete individuals.

Typical dosing: 2,000–5,000 IU D3 daily with food; 100–200mcg K2 (MK-7). Blood testing (25-OH vitamin D) is recommended to calibrate dosing.

Magnesium

Magnesium is a cofactor in over 300 enzymatic reactions, including DNA synthesis and repair, protein synthesis, and mitochondrial energy production. Despite its fundamental importance, deficiency is common in older adults due to dietary inadequacy and reduced absorption with age.

Key evidence:

• Epidemiological studies consistently associate higher magnesium intake with reduced risk of cardiovascular disease, type 2 diabetes, and all-cause mortality.
• Supplementation trials show improvements in blood pressure, insulin sensitivity, and sleep quality.
• Magnesium plays a direct role in DNA repair processes relevant to genomic stability.
• The form matters: magnesium glycinate and magnesium malate tend to be better tolerated and absorbed than magnesium oxide.

Hallmarks addressed: genomic instability (DNA repair cofactor), mitochondrial dysfunction, deregulated nutrient sensing, chronic inflammation.

Evidence quality: Strong epidemiological base; RCT evidence solid for specific outcomes.

Typical dosing: 200–400mg elemental magnesium daily, preferably as glycinate or malate.

Omega-3 Fatty Acids (High-Quality Fish Oil)

Omega-3 fatty acids — particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — have robust evidence for anti-inflammatory effects and cardiovascular protection. A critical caveat about quality is worth emphasizing: oxidized fish oil may cause harm rather than benefit, making source and freshness more important here than with many other supplements.

Key evidence:

• The REDUCE-IT trial showed that high-dose EPA (4g/day as icosapentaenoic acid) significantly reduced cardiovascular events in high-risk patients. Note: some debate exists about whether the mineral oil placebo inflated effect sizes, but the directional finding is widely accepted.
• The VITAL trial showed that omega-3 supplementation significantly reduced the risk of cardiovascular events in people who did not regularly eat fish.
• Strong evidence for anti-inflammatory effects, reduced triglycerides, and possible cognitive benefits in older adults.

Hallmarks addressed: chronic inflammation (strong), altered intercellular communication, possible epigenetic effects.

Evidence quality: Good to strong. EPA-specific evidence is particularly robust.

Typical dosing: 1–4g combined EPA+DHA daily. Choose triglyceride-form omega-3s over ethyl ester forms for better absorption. Refrigerate after opening.

High-Quality Multivitamin

The value of multivitamins has long been debated, and the debate has recently shifted. Earlier large trials showed modest or no benefit — but those trials often used low-quality formulations. Newer research presents a more positive picture, particularly for cognitive health.

Key evidence:

• The COSMOS-Mind trial (2022, American Journal of Clinical Nutrition) found that daily multivitamin supplementation over three years significantly slowed cognitive aging in older adults. The effect size was equivalent to approximately 1.8 years of reduced cognitive aging — a meaningful result that surprised many researchers.
• Multivitamins correct subclinical deficiencies that are common in older adults even in wealthy countries (B12, folate, zinc, iodine, etc.).
• Benefit is likely greater in people with dietary gaps — which is common with aging due to reduced appetite and absorption.

Hallmarks addressed: depends on formulation, but typically genomic stability (B vitamins for methylation and DNA repair), immune function, and mitochondrial support.

Evidence quality: Improved significantly with recent COSMOS data. A reasonable foundational supplement for most older adults.

Quality note: Choose a formulation without excessive iron (unless deficient), with methylated B vitamins (methylfolate, methylcobalamin), and from a reputable manufacturer with third-party testing.

TIER 2 — Promising Human Data + Strong Mechanistic Basis

These supplements have credible human evidence but either the trials are smaller, shorter, or the specific anti-aging outcomes are less conclusively established than Tier 1 compounds.

NAD+ Precursors: NR and NMN

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme that declines significantly with age. NAD+ is essential to mitochondrial energy production, DNA repair, and the activity of sirtuins — a family of longevity-associated enzymes.

The mechanistic case is compelling:

• NAD+ levels decline 40-60% between young adulthood and old age in humans
• NAD+ is required for SIRT1, SIRT3, and SIRT6 activity — all associated with longevity pathways
• Animal studies show dramatic lifespan and healthspan benefits from NAD+ restoration

Human evidence:

• Multiple RCTs confirm that both NR and NMN reliably increase blood NAD+ levels in humans. This is established.
• Small human trials show improvements in muscle function, arterial stiffness, and some metabolic markers.
• However, the critical question — does higher NAD+ translate to meaningful anti-aging outcomes in humans? — remains open. Large, long-term RCTs are underway but not yet complete.

ITP note: NR was tested by the ITP (2016 cohort, 1000 ppm) and did not show lifespan extension in either sex. This does not invalidate the human biomarker data, but it is worth noting given the ITP’s status as a gold-standard longevity test.

Hallmarks addressed: mitochondrial dysfunction, genomic instability (via PARP activation), deregulated nutrient sensing (sirtuin pathways), cellular senescence.

Evidence quality: Mechanistically strong; NAD+ elevation in humans confirmed; clinical outcome data still maturing.

Typical dosing studied: NR: 300–1,000mg/day; NMN: 250–1,200mg/day. Both forms appear effective at raising NAD+.

Alpha-Ketoglutarate (AKG): Calcium AKG and Arginine AKG

Alpha-ketoglutarate (AKG) is a key intermediate in the Krebs cycle (mitochondrial energy production) and a required cofactor for several classes of enzymes involved in epigenetic regulation. AKG levels decline substantially with age. It is available as calcium alpha-ketoglutarate (Ca-AKG) and arginine alpha-ketoglutarate (AAKG).

Key evidence:

• AKG extended lifespan in Caenorhabditis elegans (roundworm) models by up to 50% and showed benefits in mouse models.
• A 2020 study (Asadi Shahmirzadi et al., Cell Metabolism) found that Ca-AKG extended lifespan and dramatically compressed morbidity in C57BL/6 mice, with treated animals showing reduced frailty, improved gait, and decreased inflammatory cytokines.
• A 2021 human pilot study (Demidenko et al.) found that Ca-AKG supplementation in older adults was associated with reductions in biological age as measured by DNA methylation clocks — a meaningful finding, though the study was small and observational in nature.
• Ca-AKG and AAKG differ in their secondary effects: AAKG also provides arginine, a precursor to nitric oxide with vasodilatory and cardiovascular effects; Ca-AKG provides calcium and avoids the arginine pathway. The choice between them may matter depending on individual health context.
• AKG serves as a cofactor for TET enzymes and histone demethylases, directly connecting it to epigenetic regulation — one of the core hallmarks of aging.

ITP note: When the ITP tested AKG (2020 cohort, 20,000 ppm, starting at 18 months) in their genetically heterogeneous UM-HET3 mice, it did not show lifespan extension — failing to replicate the earlier result in inbred C57BL/6 mice. A second ITP test starting at an earlier age (7 months) is currently in progress. The morbidity compression and human methylation clock data remain compelling, but intellectual honesty requires noting this discrepancy with the ITP’s more rigorous model.

Hallmarks addressed: epigenetic alterations (strong mechanistic link), mitochondrial dysfunction, deregulated nutrient sensing.

Evidence quality: Strong in single-strain animal models and mechanistically; promising but limited in humans. The ITP result introduces some uncertainty about lifespan effects specifically, though healthspan benefits may still be real. The 2021 methylation clock data is intriguing but needs replication.

Typical dosing studied: 1,000–3,000mg AKG daily. Ca-AKG preferred for pure AKG activity; AAKG if NO-related cardiovascular effects are also desired.

Astaxanthin

Astaxanthin is a xanthophyll carotenoid derived primarily from the microalga Haematococcus pluvialis. It stands out among antioxidants for its exceptional potency — with an oxygen radical absorbance capacity (ORAC) estimated at 100–500 times higher than alpha-tocopherol (vitamin E) and considerably greater free radical scavenging activity than beta-carotene, lutein, and lycopene. Unlike many antioxidants, astaxanthin spans the entire cell membrane, providing protection on both sides of the lipid bilayer.

Astaxanthin holds a notable distinction in longevity research: it was the first supplement (as distinct from a pharmaceutical compound) to show ITP-confirmed lifespan extension in mice. In the 2019 ITP cohort, astaxanthin at 4000 ppm increased median lifespan in male mice. The ITP was sufficiently impressed to advance astaxanthin to Stage II testing — additional cohorts at 800 ppm, including a males-only late-start group, are currently in progress.

Key human evidence:

• A systematic review and meta-analysis of nine randomized controlled trials found that oral astaxanthin supplementation improved skin moisture, elasticity, and wrinkle depth — markers of skin aging driven by oxidative damage and inflammation.
• A meta-analysis of 12 RCTs involving 380 participants found that astaxanthin reduced blood malondialdehyde (a marker of oxidative stress), improved superoxide dismutase activity, and reduced serum isoprostane levels.
• Human clinical trials have shown astaxanthin reduces CRP (C-reactive protein) by over 20% in eight weeks, improves immune markers in healthy women, and shows benefits for cardiovascular markers including improved endothelial function.
• Small human trials in elderly subjects (12 mg/day for 12 weeks) showed improvements in cognitive and psychomotor function, along with reduced phospholipid hydroperoxides — compounds that accumulate in people with dementia.

Hallmarks addressed: chronic inflammation (strong), oxidative stress (related to proteostasis and genomic stability), mitochondrial dysfunction, altered intercellular communication.

Evidence quality: ITP-positive in males (with Stage II in progress); multiple human RCTs for inflammation, oxidative stress, skin aging, immune function, and early cognitive data. The human trials are generally smaller and shorter than ideal, and more large-scale aging-specific RCTs would strengthen the case. But the combination of ITP validation and breadth of human data makes a strong argument for Tier 2 placement.

Typical dosing studied: 4–12mg/day in human trials. The natural (H. pluvialis-derived) form is preferred over synthetic astaxanthin.

Beta-Alanine (Carnosine Precursor)

Beta-alanine is the rate-limiting precursor to carnosine, a dipeptide (beta-alanyl-L-histidine) found at high concentrations in muscle and brain tissue. Carnosine levels decline with age. Carnosine itself has poor oral bioavailability — it is broken down in the gut — making beta-alanine supplementation the practical way to raise tissue carnosine levels.

• Carnosine has multiple mechanisms relevant to aging:

• pH buffering in muscle — relevant to exercise capacity and muscle fatigue
• Anti-glycation effects — carnosine inhibits the formation of advanced glycation end-products (AGEs), which accumulate with age and damage proteins
• Antioxidant and metal chelating activity
• Potential neuroprotective effects

Human evidence:

• Well-established: beta-alanine reliably raises muscle carnosine in humans, which improves high-intensity exercise performance and reduces fatigue.
• Anti-aging evidence in humans is less direct, though carnosine’s anti-glycation properties are mechanistically relevant to multiple age-related conditions including cardiovascular disease, diabetes complications, and neurodegeneration.
• Note: beta-alanine commonly causes a harmless tingling sensation (paresthesia) at higher doses; slow-release formulations reduce this.

Hallmarks addressed: loss of proteostasis (anti-glycation), mitochondrial support in muscle tissue.

Evidence quality: Strong for exercise performance and carnosine elevation; anti-aging outcome data in humans limited but mechanistically compelling.

Typical dosing: 3.2–6.4g/day, ideally as slow-release formulation.

L-Carnitine and Acetyl-L-Carnitine (ALCAR)

Carnitine plays a critical role in mitochondrial fatty acid metabolism — it transports long-chain fatty acids across the mitochondrial membrane for energy production. Carnitine levels decline with age. Acetyl-L-carnitine (ALCAR) is a form that crosses the blood-brain barrier more effectively and has additional acetyl group donation relevant to neurotransmitter synthesis.

Key evidence:

• A landmark combination study by Ames et al. found that ALCAR combined with alpha-lipoic acid improved mitochondrial function and cognitive performance in older animals, with some human follow-up studies supporting cognitive benefits.
• Several human RCTs show ALCAR improving cognitive function, particularly in mild cognitive impairment.
• L-carnitine supplementation has shown benefits for sarcopenia (muscle loss with aging), particularly in older adults with low dietary carnitine (vegetarians and vegans, who typically consume very little).
• In older adults, L-carnitine supplementation has shown improvements in physical and cognitive fatigue in some trials.

Hallmarks addressed: mitochondrial dysfunction (primary), stem cell exhaustion (via muscle preservation), altered intercellular communication.

Evidence quality: Moderate to good, particularly for cognitive outcomes and in populations with low baseline carnitine.

Typical dosing: ALCAR: 500–2,000mg/day for cognitive effects. L-carnitine: 1,000–3,000mg/day for metabolic and muscle effects.

TIER 3 — Compelling but Earlier Stage — Worth Watching

These compounds have intriguing mechanisms and some suggestive evidence, but their inclusion in a “best-vetted” list requires appropriate caution. They represent areas of active research where the picture may look very different in 3–5 years.

SIRT6 Activators: Fucoidan and Icariin

SIRT6 is a member of the sirtuin family of NAD+-dependent enzymes, and it is of particular interest in longevity research. Studies have found that mice overexpressing SIRT6 live longer, and that higher SIRT6 activity is associated with improved DNA repair, telomere maintenance, and metabolic regulation. Conversely, SIRT6 deficiency accelerates aging phenotypes dramatically.

Several plant-derived compounds have been identified as SIRT6 activators:

Fucoidan

Fucoidan is a sulfated polysaccharide derived from brown seaweed (particularly Fucus vesiculosus and Undaria pinnatifida). It has been identified as a SIRT6 activator in cell-based studies.

• Human trials exist primarily in cancer support and immune modulation contexts; direct anti-aging human RCTs are limited.
• Fucoidan has anti-inflammatory, antioxidant, and anticoagulant properties that may be independently relevant.
• Note: anticoagulant effects mean caution is warranted for people on blood thinners.

Icariin

Icariin is the active flavonoid from Epimedium (Horny Goat Weed), a plant used in traditional Chinese medicine. It is one of the most potent natural SIRT6 activators identified to date in laboratory studies.

• Cell and animal studies show icariin activating SIRT6, improving DNA repair, reducing oxidative stress, and showing potential bone-protective effects.
• Some human studies exist for osteoporosis and testosterone-related outcomes, but direct anti-aging longevity trials in humans are absent.
• The SIRT6 activation angle is promising but needs human validation.

Evidence quality for both: Compelling mechanistic rationale (SIRT6 is a genuine longevity target); human anti-aging evidence currently limited. These are supplements worth watching closely as research matures.

Taurine

Taurine drew significant attention in 2023 when a study published in Science (Singh et al.) demonstrated that taurine levels decline dramatically with age in mice, monkeys, and humans — and that supplementing taurine extended lifespan and healthspan in mice and worms, while improving several health markers in middle-aged monkeys.

• Human observational data suggests higher taurine levels are associated with better cardiometabolic health.
• Human interventional trials specifically targeting aging outcomes are now underway following the 2023 Science paper.
• Taurine has an excellent safety profile and is found naturally in meat, fish, and dairy.

ITP note: Taurine entered ITP testing in the 2025 cohort and results are pending. A positive result could significantly strengthen the case for taurine and potentially move it into Tier 2.

Evidence quality: The 2023 Science paper was landmark-level, but human RCT data for aging outcomes is still pending. A strong candidate to move into Tier 2 in the coming years.

Low-Dose Lithium

Lithium is best known as a psychiatric medication (at gram-level doses), but epidemiological and animal research on very low doses — in the range found naturally in some drinking water supplies — has generated genuine interest in longevity contexts.

• Epidemiological studies from regions with naturally higher lithium in drinking water show lower rates of all-cause mortality, suicide, and neurodegenerative disease.
• Animal studies show lifespan extension with low-dose lithium in multiple model organisms.
• Proposed mechanisms include GSK-3beta inhibition, autophagy enhancement, and neuroprotective effects.
• Human interventional trial data at low (micronutrient-range) doses is sparse but promising.

Evidence quality: Intriguing but too preliminary for confident recommendation. At doses found in supplements (typically 1–5mg), safety appears good, but more human data is needed.

Epicatechin

Epicatechin is a flavanol found naturally in cocoa, dark chocolate, green tea, and various fruits. It drew significant attention in the longevity field in 2025 when it became one of the newest supplements to show ITP-confirmed lifespan extension. In the 2021 ITP cohort (published September 2025), epicatechin increased median lifespan by approximately 5% and 90th-percentile survival by approximately 6% in male mice. The effect was not seen in females, consistent with the male bias observed for most ITP-positive compounds.

Key evidence:

• The ITP result is significant because it comes from the most rigorous mammalian longevity testing program available, using genetically diverse mice across three independent sites.
• Earlier mouse studies had shown that epicatechin supplementation in aged mice dramatically increased survival (from 39% to 69% over 37 weeks), improved physical activity, and delayed skeletal muscle degeneration.
• Mechanistically, epicatechin promotes mitochondrial biogenesis (via upregulation of PGC-1α and related pathways), increases nitric oxide bioavailability through eNOS activation, and decreases myostatin (which promotes muscle wasting) while increasing follistatin (which promotes muscle growth).
• Small human studies have shown improvements in endothelial function, treadmill walking capacity, mitochondrial function, grip strength, and muscle mass — including in diabetic and elderly populations.
• Epicatechin reversed age-related declines in the nicotinate and nicotinamide (NAD) pathway in both serum and skeletal muscle of aged mice, suggesting a mechanistic link to NAD+ biology.

Hallmarks addressed: mitochondrial dysfunction, stem cell exhaustion (via muscle preservation), altered intercellular communication (endothelial function, NO signaling).

Evidence quality: ITP-positive in males (modest effect size); compelling earlier mouse studies; early but promising human data on vascular function, muscle, and mitochondria. The effect size in the ITP was more modest than some other positive compounds, and the human evidence base is still small. Worth watching closely as more data emerges.

Typical dosing studied: Human studies have used doses ranging from approximately 1–2 mg/kg/day. Cocoa powder is the richest dietary source; darker, less processed chocolate retains more epicatechin. Supplement forms are also available.

Summary: Evidence Overview

The following table summarizes the supplements discussed, their evidence tier, and the hallmarks of aging they most directly address.

Supplement	Tier	Primary Hallmarks Addressed
GlyNAC	1	Mitochondrial dysfunction, genomic instability, chronic inflammation, oxidative stress
Creatine	1	Stem cell exhaustion (muscle), mitochondrial dysfunction, cognitive aging
Vitamin D3 + K2	1	Intercellular communication, chronic inflammation, genomic stability
Magnesium	1	Genomic instability, mitochondrial dysfunction, nutrient sensing
Omega-3s (EPA/DHA)	1	Chronic inflammation, intercellular communication
Multivitamin	1	Genomic stability, immune function, mitochondrial support
NAD+ Precursors (NR/NMN)	2	Mitochondrial dysfunction, genomic instability, sirtuin pathways, senescence
Alpha-Ketoglutarate (AKG)	2	Epigenetic alterations, mitochondrial dysfunction, nutrient sensing
Astaxanthin	2	Chronic inflammation, oxidative stress, mitochondrial dysfunction, intercellular communication
Beta-Alanine (Carnosine)	2	Loss of proteostasis (anti-glycation), mitochondrial support
L-Carnitine / ALCAR	2	Mitochondrial dysfunction, stem cell exhaustion, cognitive aging
Fucoidan (SIRT6)	3	Genomic instability, epigenetic alterations (via SIRT6)
Icariin (SIRT6)	3	Genomic instability, epigenetic alterations (via SIRT6)
Taurine	3	Multiple hallmarks (research ongoing)
Low-dose Lithium	3	Autophagy, neurodegeneration, intercellular communication
Epicatechin	3	Mitochondrial dysfunction, stem cell exhaustion (muscle), intercellular communication

Conclusion

The supplement marketplace is vast, the marketing is aggressive, and the evidence for most products is weak. But within that landscape, a meaningful subset of compounds has earned genuine scientific credibility — through human clinical trials, through rigorous mammalian testing programs like the ITP, and through mechanistic research that maps directly onto the recognized biology of aging.

The supplements highlighted in Tier 1 have the strongest case for most older adults: GlyNAC, creatine, vitamin D3, magnesium, omega-3s, and a quality multivitamin. Tier 2 compounds are worth serious consideration for those who want to go further, with the understanding that the evidence is still developing. Tier 3 supplements represent an exciting frontier — worth watching, and worth discussing with a knowledgeable clinician if you are inclined to explore them.

Three principles are worth holding onto:

• Evidence quality over marketing claims. If a supplement’s primary selling point is a celebrity endorsement or a dramatic testimonial rather than peer-reviewed research, approach with skepticism.
• Biomarkers matter, even when lifespan can’t be measured. Tracking inflammation markers, metabolic panels, body composition, cognitive function, and grip strength gives you real data about how your body is responding.

The combination problem is real. We don’t yet know how most of these supplements interact when taken together. A thoughtful, monitored approach — rather than taking everything at once — is the wisest course.

Aging biology is advancing rapidly. What sits in Tier 3 today may have compelling human trial data within five years. Staying current with the research — and maintaining appropriate skepticism about premature claims — is the best long-term strategy for navigating this field.

This article will be updated as new research emerges. For the most current information on anti-aging supplements and longevity research, visit NewLifeLongevity.com.

Key References

Kumar P, Liu C, Hsu JW, Chacko S, Minard C, Jahoor F, Sekhar RV. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine, 11(3):e372.

Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. (2023). Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: A randomized clinical trial. Journals of Gerontology: Medical Sciences, 78(1):75–89.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2):243–278.

Singh P, Gollapalli K, Mangiola S, et al. (2023). Taurine deficiency as a driver of aging. Science, 380(6649):eabn9257.

Demidenko O, Barardo D, Budovskii V, Finnemore R, Palmer FR, Kennedy BK, Budovskaya YV. (2021). Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY), 13(22):24485–24499.

Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley C, Riley R, Kaplowitz B, Gan G, Kim DE, Kuehnemann C, Bhaumik D, Campisi J, Kennedy BK, Lithgow GJ. (2020). Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metabolism, 32(3):447–456.

Harrison DE et al. (multiple years). NIA Interventions Testing Program results. Aging Cell.

Strong R, Miller RA, Nelson JF, Bogue MA, Colca JR, Denzel M, Diaz V, Finck BN, Gladyshev VN, et al. (2025). Extension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice. GeroScience.

Harrison DE, Strong R, Reifsnyder P, et al. (2024). Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. GeroScience, 46(5):4657–4670.

Miller RA, Harrison DE, Astle CM, Bogue MA, Brind J, Fernandez E, Flurkey K, Javors M, Ladiges W, Leeuwenburgh C, et al. (2019). Glycine supplementation extends lifespan of male and female mice. Aging Cell, 18(3):e12953.

Baker LD, Manson JE, Rapp SR, Sesso HD, Gaussoin SA, Shumaker SA, Espeland MA. (2023). Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial. Alzheimer’s & Dementia, 19(4):1308–1319.

Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1):11–22.

Manson JE, Cook NR, Lee IM, et al.; VITAL Research Group. (2019). Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine, 380(1):33–44.

Si H, Wang X, Zhang L, Parnell LD, Ahmed B, LeRoith T, Ansah TA, Zhang L, Li J, Ordovás JM, Si H, Liu D, Lai CQ. (2019). Dietary epicatechin improves survival and delays skeletal muscle degeneration in aged mice. FASEB Journal, 33(1):965–977.

Galasso C, Ferrara I, Ferruzza S, et al. (2021). Therapeutic uses of natural astaxanthin: An evidence-based review focused on human clinical trials. Pharmacological Research, 166:105479.

Davinelli S, Nielsen ME, Scapagnini G. (2018). Astaxanthin in skin health, repair, and disease: A comprehensive review. Nutrients, 10(4):522.